Approval · Notice of Compliance 31323 · 2023
FOQUEST: Notice of Compliance 31323
Issued July 27, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 31323
- Date
- July 27, 2023
- Company
- Elvium Life SciencesToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Change the format of the 25 mg bottle label. Update the address of the Manufacturer on said label.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| FOQUEST | Not yet assigned | — |
Medicinal ingredients
- METHYLPHENIDATE HYDROCHLORIDE 25 MG per CAP